MARKET INSIGHTS
Global Mesalazine API market size was valued at USD 190 million in 2024. The market is projected to grow from USD 197 million in 2025 to USD 260 million by 2034, exhibiting a CAGR of 3.7% during the forecast period. North America accounted for the largest regional share at USD 52 million in 2024, growing at a steady 3.2% CAGR.
Mesalazine (5‑aminosalicylic acid) is an active pharmaceutical ingredient primarily used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. As a first‑line therapy, it works locally in the gastrointestinal tract to reduce inflammation. The API exists in multiple purity grades (97%, 98%, 99%) and is formulated into various drug delivery forms including tablets, capsules, and rectal formulations.
Market growth is driven by rising IBD prevalence worldwide, with over 3 million cases reported in the US and Europe alone. While biosimilars present competition, the market continues expanding due to increasing diagnosis rates and the development of novel delivery mechanisms. Key manufacturers like Cambrex Corporation and Divis Laboratories are investing in capacity expansions to meet growing demand, particularly in emerging Asian markets where healthcare access is improving.
Mesalazine API Market – View in Detailed Research Report
Market Forecast Overview
The forecast framework anchors on 2025 as the base year, with 2026 as an estimated interim milestone, projecting the market to reach USD 260 million by 2034.
Top 10 Companies in the Mesalazine API Market
1️⃣ Cambrex Corporation
Headquarters: Wilmington, Delaware, USA
Key Offering: High‑purity mesalazine API (99%) for oral and rectal formulations
Cambrex’s proprietary synthesis route delivers consistently high purity with reduced impurity profiles, enabling seamless integration into branded dosage forms. The company’s focus on process scalability positions it to support both large‑volume generics and specialty products.
Sustainability & Growth Initiatives:
- Investment in green chemistry to lower CO₂ footprint
- Expansion of manufacturing footprint in North America to reduce lead times
- Strategic partnerships with contract manufacturers to accelerate product launches
2️⃣ Divis Laboratories
Headquarters: Bangalore, India
Key Offering: Cost‑effective mesalazine API (97–99%) for generics
Divis’s robust supply chain and flexible capacity allow it to meet fluctuating demand, especially in the Asian market where IBD prevalence is rising. The firm’s emphasis on quality assurance aligns with global GMP standards.
Sustainability & Growth Initiatives:
- Expansion of GMP‑certified facilities in the Indian subcontinent
- Adoption of energy‑efficient synthesis modules
- Collaboration with regional hospitals for clinical trials
3️⃣ PharmaZell
Headquarters: Bonn, Germany
Key Offering: Specialty mesalazine API for advanced drug delivery systems
PharmaZell’s expertise in complex chemical synthesis supports the production of high‑purity APIs required for multi‑matrix and pH‑dependent release formulations, catering to pharmaceutical companies seeking differentiation.
Sustainability & Growth Initiatives:
- Investment in renewable energy for manufacturing sites
- Development of closed‑loop waste management processes
- Strategic alliances with European pharma groups
4️⃣ Syntese A/S
Headquarters: Copenhagen, Denmark
Key Offering: High‑grade mesalazine API (99%) for specialty and generic markets
With a strong focus on process efficiency, Syntese delivers APIs that meet stringent European regulatory expectations while maintaining competitive pricing.
Sustainability & Growth Initiatives:
- Implementation of water‑recycling systems in production lines
- Carbon‑offset projects to neutralise manufacturing emissions
- Partnerships with Nordic healthcare providers for product validation
5️⃣ Chemi SpA
Headquarters: Milan, Italy
Key Offering: Versatile mesalazine API (97–99%) for oral and rectal dosage forms
Chemi’s integrated synthesis platform enables rapid scale‑up, supporting both large pharmaceutical contracts and boutique generics.
Sustainability & Growth Initiatives:
- Adoption of bio‑based feedstocks for key intermediates
- Enhanced waste‑minimisation protocols across the supply chain
- Collaboration with Italian health authorities for product approvals
6️⃣ Ipca Laboratories
Headquarters: Hyderabad, India
Key Offering: Economical mesalazine API (97%) for generics
Ipca’s extensive production network supports rapid distribution across emerging markets, ensuring timely supply for high‑volume demand.
Sustainability & Growth Initiatives:
- Implementation of energy‑saving technologies in production facilities
- Strengthening of quality systems to meet international GMP requirements
- Active participation in IBD awareness campaigns
7️⃣ Hangzhou Brother
Headquarters: Hangzhou, China
Key Offering: Competitive mesalazine API (97–98%) for domestic and export markets
Hangzhou Brother’s cost‑effective manufacturing model has positioned it as a key supplier to both Chinese and global pharmaceutical companies.
Sustainability & Growth Initiatives:
- Investment in advanced purification units to achieve 99% purity
- Partnerships with Chinese regulatory bodies to streamline approvals
- Commitment to reducing water consumption in production
8️⃣ Lianyungang Fengheng Biopharm
Headquarters: Lianyungang, China
Key Offering: High‑purity mesalazine API (99%) for specialty formulations
Fengheng’s focus on stringent quality controls aligns with the demands of premium drug manufacturers seeking superior API performance.
Sustainability & Growth Initiatives:
- Deployment of waste‑heat recovery systems in synthesis units
- Active engagement with local communities to promote IBD awareness
- Exploration of bio‑based catalysts for greener processes
9️⃣ Lasa Loboratory
Headquarters: Mumbai, India
Key Offering: Versatile mesalazine API (97–99%) for diverse dosage forms
With a strong presence in the Indian generic market, Lasa Loboratory supports local manufacturers with reliable API supplies.
Sustainability & Growth Initiatives:
- Adoption of low‑energy synthesis processes
- Collaboration with Indian health ministries for product distribution
- Investment in employee training for GMP excellence
🔟 Corden Pharma Bergamo
Headquarters: Bergamo, Italy
Key Offering: High‑purity mesalazine API (99%) for specialty and generic sectors
Corden’s strong engineering capabilities enable rapid scale‑up for both large and niche pharmaceutical clients.
Sustainability & Growth Initiatives:
- Implementation of renewable energy sources in manufacturing plants
- Participation in European sustainability certification programs
- Strategic collaborations with Italian pharma groups
Download FREE Sample Report
Mesalazine API Market – View in Detailed Research Report
Outlook
The trajectory of the Mesalazine API market is shaped by evolving therapeutic paradigms and a steady rise in IBD cases. The shift toward precision drug delivery and the integration of mesalazine into combination regimens are likely to sustain demand. Companies that align their production strategies with regulatory expectations and patient‑centric delivery models will capture the most value.
Future Trends
- Enhanced focus on ultra‑high purity APIs to support next‑generation formulations.
- Accelerated adoption of green synthesis routes to reduce environmental impact.
- Growing importance of digital supply‑chain solutions for real‑time quality monitoring.
- Expansion of mesalazine use into new therapeutic areas driven by emerging clinical evidence.
- Top 10 Companies in the Russia Copper Scrap Market (2026): Market Leaders Powering Global Recycling - September 29, 2026
- Top 10 Companies in the Acoustical Barrier With Absorber Market (2026): Market Leaders Powering Global Growth - September 29, 2026
- Top 10 Companies in the Lightweight Refractory Insulation Bricks Market (2026): Market Leaders Driving Industrial Thermal Efficiency - September 29, 2026